CVRx, Inc. CVRX 深 滬
等待開盤 10-23 09:30:00 美东时间
9.93
-0.140
-1.39%
華盛通- 最 高10.07
- 今 開10.07
- 成交量 10.78万股
- 最 低 9.71
- 昨 收 10.07
- 總市值 2.59亿
- 52周最高 18.55
- 市盈率 靜 --
- 換手率 0.41%
- 52周最低 4.2993
- 委 比 -62.61%
- 總股本 2607.26万
- 歷史最高 33.135
- 量 比 0.48
- 振 幅 3.57%
- 歷史最低 4.2993
- 每 手 1
- 風險率 3.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
CervoMed Inc. announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer, bringing nearly 20 years of biotech industry experience. This move aims to prepare for late-stage development and market readiness of neflamapimod, a potential treatment for dementia with Lewy bodies. Dr. Winton’s expertise in commercialization and leadership in neurology treatments positions CervoMed for growth and innovation.
10-07 12:00
CVRx shares are trading lower after the company reported mixed Q2 financial results and narrowed its FY25 sales guidance.
CVRx shares are trading lower after the company reported mixed Q2 financial res...
08-05 23:35
Cantor Fitzgerald Reiterates Overweight on CVRx, Maintains $11 Price Target
Cantor Fitzgerald analyst Ross Osborn reiterates CVRx (NASDAQ:CVRX) with a Overweight and maintains $11 price target.
08-05 20:25
CVRx Appoints Brent Binkowski as New COO
An announcement from CVRx ( ($CVRX) ) is now available. On August 4, 2025, CVRx...
08-05 04:29
CVRx Sees Q3 Sales $13.700M-$14.700M vs $14.537M Est
CVRx (NASDAQ:CVRX) sees Q3 sales of $13.700 million-$14.700 million vs $14.537 million analyst estimate.
08-05 04:11
CVRx Narrows FY2025 Sales Guidance from $55.000M-$58.000M to $55.000M-$57.000M vs $56.086M Est
CVRx (NASDAQ:CVRX) narrows FY2025 sales outlook from $55.000 million-$58.000 million to $55.000 million-$57.000 million vs $56.086 million estimate.
08-05 04:11
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025
CVRx, Inc. plans to release second quarter 2025 financial and operating results on August 4, 2025, after market close. A conference call and webcast will be held at 4:30pm ET the same day. CVRx is a medical device company specializing in neuromodulation solutions for cardiovascular diseases, including Barostim™, the first FDA-approved therapy for heart failure.
07-21 20:30
CVRx's Barostim Implant Set for $45K Medicare Reimbursement Under Proposed Outpatient Rule
CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the
07-16 19:32
CVRx Announces Positive News on Outpatient Payment for Barostim
CVRx announced that CMS has proposed maintaining the Barostim implant procedure in APC 1580 with an approximate $45,000 payment for outpatient procedures. CMS is also seeking comments on a potential Level 6 Neurostimulator APC. This follows positive developments in reimbursement rates, including a higher MS-DRG for inpatient procedures and transitioning to Category I CPT codes for physician payments. These updates highlight the clinical value of ...
07-16 11:30
